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The ectopic gluconeogenic activity of
PGC-1a is a causative factor for
hyperglycemia. Sun et al. show that PCAF
acetylates PGC-1a and thus triggers its
proteasomal degradation. By
downregulating PGC-1a activity, PCAF
improves glucose homeostasis and
insulin sensitivity in the obese mice.
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SUMMARY
PGC-1a plays a central role in hepatic gluconeogen-
esis and has been implicated in the onset of type 2
diabetes. Acetylation is an important posttransla-
tional modification for regulating the transcriptional
activity of PGC-1a. Here, we show that PCAF is a
pivotal acetyltransferase for acetylating PGC-1a in
both fasted and diabetic states. PCAF acetylates
two lysine residues K328 and K450 in PGC-1a,
which subsequently triggers its proteasomal degra-
dation and suppresses its transcriptional activity.
Adenoviral-mediated expression of PCAF in the
obese mouse liver greatly represses gluconeogenic
enzyme activation and glucose production and im-
proves glucose homeostasis and insulin sensitivity.
Moreover, liver-specific knockdown of PCAF stimu-
lates PGC-1a activity, resulting in an increase in
blood glucose and hepatic glucose output. Our
results suggest that PCAF might be a potential phar-
macological target for developing agents against
metabolic disorders associated with hyperglycemia,
such as obesity and diabetes.
INTRODUCTION
Obesity and the associated disorder type 2 diabetes have
become leading causes of adult morbidity and mortality world-
wide (Saltiel, 2001; Schenk et al., 2008). Hyperglycemia is a
hallmark of severe obesity and type 2 diabetes (Bornfeldt and
Tabas, 2011; Zimmet et al., 2001). Excessive hepatic glucose
production (HGP) is a major contributor for fasting hyperglyce-
mia in diabetes (Saltiel, 2001; Shulman, 2000). Hepatic gluco-
neogenesismainly accounts for HGP in diabetes, which is largely
controlled by a set of transcriptional factors including CREB,
FoxO1, C/EBPs, HNF4a, and GR (Herzig et al., 2001; Lin et al.,
2004; Puigserver et al., 2003; Yoon et al., 2001). PGC-1a was
initially identified as a cold-inducible coactivator for PPARg in
brown fat (Puigserver et al., 1998). Subsequently, accumulating
evidence reveals that PGC-1a regulates several metabolic
processes including mitochondrial biogenesis and respiration,
muscle-fiber-type switching, and fatty acid synthesis (Finck
et al., 2006; Lehman et al., 2000; Lin et al., 2002; Puigserver
et al., 2003; Wu et al., 1999). Additionally, adenoviral-mediated
expression of PGC-1a in the hepatocytes strongly activates
the entire program of gluconeogenesis and increased glucose
output (Yoon et al., 2001), leading to a conclusion that PGC-1a
is a key transcriptional coactivator in hepatic gluconeogenesis.
Notably, PGC-1amodulates the gluconeogenic pathway in fast-
ing and diabetic states. For example, PGC-1amRNA level in the
liver is rapidly induced following short-term fasting (Yoon et al.,
2001). Likewise, hepatic PGC-1a gene expression is robustly
increased in the diabetic mice (Yoon et al., 2001). Furthermore,
specific knockout of PGC-1a in mouse liver results in abnormal
HGP and eventually leads to a reduction in blood glucose level
(Handschin et al., 2005). Liver-specific knockdown of PGC-1a
in the diabeticmice is sufficient to normalize blood glucose levels
and to improve systemic glucose homeostasis (Koo et al., 2004).
Therefore, manipulating the hepatic PGC-1a transcriptional
activity is an effective strategy for treating metabolic disorders
in which hepatic glucose output is dysregulated.
Acetylation, an important posttranslationalmodification (PTM),
is involved in multiple cellular events including growth, prolifera-
tion, differentiation, survival, and apoptosis (Sadoul et al., 2008).
Histone acetyltransferases (HATs) are the enzymes catalyzing
protein acetylation, whereas histone deacetylases (HDACs) are
responsible for protein deacetylation (Roth et al., 2001). HATs
and HDACs govern gene silence or activation by catalyzing the
acetylation or deacetylation of histones, respectively. In addition
to posttranslationally modifying histones, HATs and HDACs can
also modify nonhistone proteins, such as p27, Skp2, and FoxO1
(Inuzuka et al., 2012; Motta et al., 2004; Pe´rez-Luna et al., 2012).
PGC-1a was recently found to be acetylated and deacetylated,
respectively, byGCN5andSIRT1 for regulating its transcriptional
activity (Lerin et al., 2006; Rodgers et al., 2005). In particular,
PGC-1a acetylation by GCN5 attenuates its activity, whereas
its deacetylation by SIRT1 enhances its activity. Multiple lysine
residues in PGC-1a were identified as the deacetylation sites
by SIRT1 (Rodgers et al., 2005). In contrast, the potential acety-
lation sites in PGC-1a by GCN5 or other HATs remain yet
to be characterized (Lerin et al., 2006). Moreover, whether
and which HAT is the key acetyltransferase responsible for the
upregulation of PGC-1a gluconeogenic activity in fasting and
diabetic states are still not understood well.
Herein, our results show that PCAF is a pivotal HAT that
acetylates PGC-1a in both fasting and diabetic states. PCAF
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acetylates K328 and K450 residues in PGC-1a, leading to its
proteasomal degradation. Adenoviral-mediated expression of
PCAF improves glucose homeostasis in the obese mice by
attenuating PGC-1a-driven hepatic gluconeogenesis. Liver-
specific knockdown of PCAF enhances the transcriptional
activity of PGC-1a and stimulates hepatic gluconeogenesis.
Together, our data suggest that PCAF might be a pharmacolog-
ical target for developing agents against hyperglycemia-associ-
ated disorders such as obesity, insulin resistance, and diabetes.
RESULTS
PCAF Reversely Correlates and Physically Interacts
with PGC-1a
It has been reported that PGC-1a acetylation suppresses its
gluconeogenic activity (Lerin et al., 2006). To elucidate whether
PGC-1a acetylation contributes to hyperglycemia in vivo, we
compared hepatic acetylated PGC-1a levels between the lean
and obese mice. As shown in Figure 1A, PGC-1a acetylation
levels (Ac-K) were mildly decreased in the diet-induced obese
(DIO) mouse livers, whereas total PGC-1a protein levels were
markedly increased. As a consequence, Ac-K/PGC-1a is sig-
nificantly reduced in the obese mice (Figure 1B). To identify
which acetyltransferase is responsible for this reduction, several
acetyltransferase protein levels were measured. The results
show that PCAF and CBP protein levels are decreased in the
DIO mice, whereas GCN5 and p300 are not altered (Figures 1A
and 1B). Furthermore, we also measured these proteins levels
in the ob/ob mice. Similarly, the Ac-K/PGC-1a is significantly
decreased in the ob/ob mice (Figures 1C and 1D). PCAF and
CBP were dramatically reduced in the ob/ob mice, whereas no
significant changes in GCN5 and p300 were observed (Figures
Figure 1. PCAF Reversely Correlates and Physically Interacts with PGC-1a
(A) Protein levels of acetylated PGC-1a, PCAF, GCN5, CBP, and p300 in the lean and diet-induced obese (DIO) mouse livers.
(B) Densitometric quantification of the immunoblot data in (A).
(C) Protein levels of acetylated PGC-1a, PCAF, GCN5, CBP, and p300 in the wild-type (WT) and ob/ob mouse livers.
(D) Densitometric quantification of the immunoblot data in (C).
(E) Physical interaction between PCAF and PGC-1a. The HEK293 cells were transfected with the plasmids expressing PCAF (left) or PGC-1a (right). IP was
performed using antibodies indicated.
(F) Physical interaction between CBP and PGC-1a. The HEK293 cells were transfected with the plasmids expressing CBP (left) or PGC-1a (right). IP was
performed using antibodies indicated.
IgG, immunoglobulin G; IP, immunoprecipitation; WCL, whole cell lysate. *p < 0.05; **p < 0.01 versus the lean or WT mice. All values represent mean ± SEM.
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1C and 1D). These data imply that the decrease in Ac-K/PGC-1a
in DIO or ob/ob mouse liver might result from the reductions in
PCAF or CBP. Coimmunoprecipitation (coIP) experiments
show that PGC-1a interacts with PCAF, but not CBP (Figures
1E and 1F). These data strongly indicate that PCAF acetyltrans-
ferase is responsible for the reduction of PGC-1a acetylation in
the obese mouse livers.
PCAF Acetylates PGC-1a and Promotes Its Degradation
We next investigated whether PCAF directly acetylates PGC-1a.
As shown in Figure 2A, PCAF dramatically enhances PGC-1a
acetylation whereas inactive PCAF (PCAF DHAT) does not.
We then investigated whether PCAF downregulation affects
PGC-1a acetylation. mRNA levels of PCAF were significantly
reduced by Ad-PCAF small hairpin RNA (shRNA) no. 2 and
no. 3 in the mouse embryonic fibroblasts (MEFs) (Figure 2B).
Consistent with the changes inmRNA levels, PCAF protein levels
were noticeably reduced by Ad-PCAF shRNA no. 2 and no. 3
(Figure 2C). Of these adenoviruses, Ad-PCAF shRNA no. 2
exhibits the best effect; hence, we chose Ad-PCAF shRNA
no. 2 for the subsequent experiments. PGC-1a acetylation was
gradually reduced along with the decrease in PCAF (Figure 2D).
These data clearly show that PCAF directly acetylates PGC-1a.
Previous studies show that acetylation affects the transcrip-
tional activity of PGC-1a (Lerin et al., 2006; Rodgers et al.,
2005). However, the underlying molecular mechanism is unclear.
Here, we noticed that PGC-1a protein levels were significantly
reduced or enhanced by PCAF overexpression or knockdown,
respectively (Figures 2A and 2D). To confirm these effects, we
ectopically expressed PGC-1a together with PCAF or inactive
Figure 2. PCAF Acetylates PGC-1a and Triggers Its Proteasomal Degradation
(A) PCAF acetylates PGC-1a in a histone acetyltransferase (HAT) activity-dependent manner.
(B and C) Adenovirus-mediated knockdown of PCAF. MEFs were infected with adenovirus expressing shRNAs against Pcaf. PCAF mRNA (B) and protein levels
(C) were measured.
(D) PCAF knockdown decreases PGC-1a acetylation in the MEFs.
(E) The decrease in PGC-1a protein level induced by PCAF in the HEK293 cells requires PCAF acetyltransferase activity.
(F) PGC-1a mRNA levels were not altered by PCAF in the HEK293 cells.
(G) PCAF promotes PGC-1a protein degradation in the HEK293 cells. CHX, cycloheximide.
(H) Densitometric quantification of the immunoblot data as shown in (G).
(I) PCAF-mediated degradation in PGC-1a via proteasome pathway. HEK293 cells were transfected with plasmids as indicated, and the cells were treated with
10 mM MG132.
*p < 0.05; **p < 0.01. All values represent mean ± SEM. See also Figure S1.
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PCAF in the human embryonic kidney 293 (HEK293) cells. PGC-
1a protein levels were reduced continuously as PCAF increases,
whereas no significant alterations were occurred by inactive
PCAF (Figure 2E). Next, we aim to explore the molecular mecha-
nism responsible for PGC-1a reduction by PCAF. We first
measured the effect of PCAF on PGC-1a mRNA level but found
that PCAF does not affect its mRNA level (Figure 2F). We then
examined whether PCAF decreases PGC-1a expression at pro-
tein level. Pulse-chase experiments show that PGC-1a protein
was gradually degraded with cycloheximide (CHX) treatment.
Interestingly, PCAF further accelerates the degradation of PGC-
1a protein (Figures 2G and 2H). The decrease in PGC-1a induced
by PCAF was almost completely restored by MG132 (Figure 2I).
Immunostaining and coIP experiments showed that PCAF and
PGC-1a colocalize in the nucleus, the primary site for acetylation
(Figures S1A and S1B). These data indicate that PGC-1a acetyla-
tion by PCAF triggers its proteasomal degradation.
PCAF Acetylates PGC-1a at Lysine Residues K328
and K450
To identify the site(s) in PGC-1a targeted by PCAF acetyltrans-
ferase for acetylation, we cotransfected the HEK293 cells with
the plasmids expressing PGC-1a and PCAF. PGC-1a was
purified by immunoprecipitation for subsequent tandem mass
spectrometry analysis. The results showed that two lysine resi-
dues K328 and K450 in PGC-1a were acetylated (Figures 3A
and 3B). These two sites are highly conserved among different
species (Figure 3C). We next examined whether these site
mutations affect PCAF-mediated acetylation on PGC-1a. The
HEK293 cells were transfected with PCAF along with wild-type
or mutated PGC-1a. The cells were treated with MG132 to
inhibit PGC-1a degradation, which will facilitate IP experiments.
PGC-1a with either K328R or K450R single-site mutation
shows decreased acetylation level by PCAF compared with
the wild-type PGC-1a (Figure 3D). Double mutations (K328R/
K450R) almost completely abolish the acetylation of PGC-1a
by PCAF. PCAF reduces the protein levels of PGC-1a, PGC-
1aK328R, and PGC-1aK450R but shows no reduction effect on
PGC-1aK328R/K450R (Figure 3E). Furthermore, the degradation
of PGC-1aK328R/K450R induced by PCAF was significantly atten-
uated (Figures 3F and 3G). These data clearly show that K328
and K450 in PGC-1a are the target acetylation sites by PCAF
and replacing both lysines with arginines would abolish the
degradation of PGC-1a induced by PCAF.
Acetylation by PCAF Attenuates PGC-1a
Gluconeogenic Activity
We next investigated whether PGC-1a acetylation by PCAF
affects its hepatic gluconeogenic activity. We transfected the
primary mouse hepatocytes with a luciferase reporter driven by
PEPCK or G6Pase promoter together with PGC-1a and PCAF.
PEPCK transcription was robustly stimulated by PGC-1a, and
this stimulation was markedly attenuated by PCAF (Figure 4A).
However, PCAF has no effect on PEPCK transcription activation
stimulated by PGC-1aK328R/K450R. Similar results were also
observed using a luciferase reporter driven by G6Pase promoter
(Figure 4A). Consistent with the luciferase assay, PCAF blocks
the increases in PEPCK and G6Pase induced by PGC-1a.
However, PCAF fails to downregulate PEPCK and G6Pase
induced by PGC-1aK328R/K450R (Figure 4B). Furthermore, we
investigated the effects of PCAF on PEPCK and G6Pase
mRNA levels. Pck1 expression was significantly enhanced by
PGC-1a, and this enhancement was blocked by PCAF, whereas
inactive PCAF has no such an effect (Figure 4C). Similar results in
G6pc expression were observed. The protein levels of PEPCK
and G6Pase were altered accordingly by PCAF and inactive
PCAF (Figure 4D). PCAF reduces the glucose production
stimulated by PGC-1a, and this effect requires acetyltransferase
activity of PCAF (Figure 4E).
To ascertain whether PCAF affects the recruitment of PGC-1a
to gluconeogenic gene promoters, we ectopically expressed
PCAF in the H4IIE cells and the cells were treated with MG132
to inhibit PGC-1a degradation. Forskolin/3-isobutyl-1-methyl-
xanthine (FSK/IMX) was used to stimulate hepatic gluconeogen-
esis. Chromatin immunoprecipitation (ChIP) analysis showed
that the recruitment of PGC-1a to Pck1 and G6pc promoters
was increased by FSK/IMX, whereas PCAF overexpression
has no effect on this recruitment (Figures S2A and S2B). It has
been reported that GCN5 could lead to PGC-1a redistribution
in a nuclear punctuate pattern (Lerin et al., 2006), raising a
prediction that GCN5, as well as PCAF, might directly affect
the coactivity of PGC-1a on gluconeogenic gene expression.
To test this hypothesis, we transfected the H4IIE cells with
GCN5 or PCAF and ChIP experiments were performed. Indeed,
the recruitment of GCN5 to Pck1 and G6pc promoters was
significantly impaired in the FSK/IMX-treated cells (Figure S2C).
However, no obvious alterations were observed with regard
to PCAF (Figure S2D). These data indicate that PGC-1a acetyla-
tion by PCAF attenuates its hepatic gluconeogenic activity
without affecting the recruitment of PGC-1a to Pck1 and G6pc
promoters.
PCAF Improves Glucose Homeostasis by Repressing
PGC-1a Activity
It has been shown that PGC-1a activity was regulated by
nutritional status (Rodgers et al., 2005; Yoon et al., 2001). To
elucidate whether PCAF is involved in this process, mice were
placed under control, fasted, and refed conditions. The mRNA
levels of PGC-1a, PEPCK, and G6Pase in the lean mouse liver
were dramatically stimulated by fasting and restored to nearly
control levels upon refeeding, whereas no significant changes
in PCAF mRNA levels were observed (Figure 5A). For the obese
mice, the mRNA levels of PGC-1a and PEPCK were not altered
by fasting andG6pc expressionwas even decreased (Figure 5B).
Pcaf expression was not altered as well. Similar to the mRNA
levels, the protein levels of PGC-1a, as well as its downstream
targets PEPCK and G6Pase, were stimulated upon fasting.
These protein levels were restored to the control levels under
refed state (Figures 5C and 5D). Interestingly, the PCAF level
decreased upon fasting and recovered upon refeeding. In the
obese mice, no significant changes in PCAF, PGC-1a, PEPCK,
andG6Pasewere observed (Figures 5E and 5F). These data indi-
cate that PCAF might act as a negative regulator of PGC-1a in
response to different nutritional status.
Therefore, PCAF likely improves glucose homeostasis by re-
pressing PGC-1a activity. To verify this possibility, we increased
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PCAF expression in the obese mouse liver by tail vein injection
with Ad-PCAF. Blood glucose level was decreased by PCAF
(Figure 5G), and plasma insulin was reduced as well (Figure 5H).
Almost 8-fold increase in Pcaf expression was observed in the
Ad-PCAF-infected mouse liver (Figure 5I). Pck1 and G6pc were
decreased significantly by PCAF, whereas PGC-1a mRNA level
Figure 3. PCAF Acetylates PGC-1a at K328 and K450
(A and B) Identification of acetylation sites in PGC-1a by tandem mass spectrometry.
(C) Sequence alignment of the putative acetylation sites of K328 and K450 in PGC-1a from different species.
(D) Mutations of K328 and K450 blocks PCAF-mediated acetylation modification on PGC-1a.
(E) Effects of PCAF on wild-type and mutated PGC-1a protein levels.
(F) Protein stability analysis of wild-type and mutated PGC-1a.
(G) Densitometric quantification of the immunoblot data as shown in (F). Results are expressed as percentage relative to levels observed at time 0.
**p < 0.01; ***p < 0.001 versus the cells transfected with PGC-1a. All values represent mean ± SEM.
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was not affected (Figure 5I). The increased PCAF results in de-
clines in PGC-1a, PEPCK, and G6Pase (Figures 5J and 5K).
Glucose tolerance was improved by PCAF, and glucose produc-
tion from pyruvate was attenuated (Figures 5L and 5M). In addi-
tion, PCAF accelerates glucose clearance rate based on the
insulin tolerance test (Figure 5N). We also analyzed the insulin
signal transduction, and the results showed that phosphorylated
Akt and GSK3b were significantly increased by PCAF (Figures
5O and 5P). To investigate whether PGC-1a plays a major role
in PCAF-mediated enhancement of glucose homeostasis, we
reconstituted PGC-1a expression in the PCAF-infected mice
and analyzed glucose metabolism. The ameliorations induced
by PCAF in blood glucose levels, Pck1 and G6pc expression,
and pyruvate tolerance were restored to the control levels (Fig-
ures S3A–S3C). The decreases in protein levels of PGC-1a,
PEPCK, and G6Pase were increased to the levels comparable
to that observed in the control mice (Figure S3D). Furthermore,
we measured liver mitochondria function because PGC-1a is
a pivotal factor for mitochondrial biogenesis (Cui et al., 2006;
Wu et al., 1999). mtDNA copy number, as well as oxygen flux
in mitochondria and mitochondrial gene expression, was not
altered by PCAF (Figures S4A–S4C). The expression levels of
three fatty-acid-oxidation-related genes, LCAD, MCAD, and
SCAD, were analyzed. Of the three genes, LCAD expression
level was decreased whereas MCAD and SCAD were not
affected (Figure S4D). These results strongly indicate that
PCAF acetyltransferase improves glucose homeostasis and
insulin sensitivity in the obese mice by repressing the gluconeo-
genic activity of PGC-1a.
PCAF Knockdown Stimulates the Gluconeogenic
Activity of PGC-1a
The observation that PCAF represses the gluconeogenic
activity of PGC-1a led us to wonder whether PCAF knockdown
stimulates PGC-1a activity. To address this issue, PCAF knock-
down in liver was achieved by tail vein injection with Ad-PCAF
shRNA. The mRNA level of PCAF was significantly reduced
in the Ad-PCAF-shRNA-no. 2-infected mice (Figure 6A). Pck1
Figure 4. PCAF Represses PGC-1a Gluconeogenic Activity
(A) Acetylation site mutation diminishes PCAF-mediated repression on PGC-1a activity. The HEK293 cells were transfected with the indicated plasmids together
with PEPCK or G6Pase reporter luciferase construct. Luciferase activity was measured 24 hr after transfection.
(B) Mutations of K328 and K450 blocks PCAF-mediated repression of PGC-1a transcriptional activity on PEPCK and G6Pase. The primary mouse hepatocytes
were infected with adenovirus as indicated. Thirty-six hours postinfection, total cell lysates were subjected to western blot analysis.
(C and D) Repression of PGC-1a transcriptional activity through PCAF acetyltransferase activity. The mRNA levels of Pck1 andG6pc (C) and the protein levels of
PEPCK, G6Pase, PGC-1a, and PCAF (D) in the primary mouse hepatocytes were analyzed.
(E) Repression of PGC-1a-stimulated glucose production in the primary mouse hepatocytes requires PCAF acetyltransferase activity.
*p < 0.05; **p < 0.01 versus the control cells. All values represent mean ± SEM. See also Figure S2.
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expression was markedly stimulated by PCAF knockdown,
whereas G6pc was not affected (Figure 6B). PCAF protein level
was dramatically reduced by Ad-PCAF shRNA no. 2, which in
turn stimulates PGC-1a and PEPCK (Figures 6C and 6D). The
acetylated PGC-1a was decreased by the reduced expression
of PCAF. G6Pase protein level was not altered by PCAF reduc-
tion. The blood glucose level was enhanced by PCAF knock-
down (Figure 6E), and glucose de novo synthesis from pyruvate
was also upregulated (Figure 6F). Next, we wished to determine
whether PCAF knockdown mediates gluconeogenesis via PGC-
1a. To address this issue, we generated adenovirus-bearing
shRNAs against PGC-1a (Ad-PGC-1a shRNA) to reduce PGC-
1a expression. Both the mRNA and protein levels of PGC-1a
were decreased dramatically in the adenovirus-infected Hepa
1-6 cells, and Ad-PGC-1a shRNA no. 1 showed the best knock-
down efficiency (Figures S5A and S5B). Thus, Ad-PGC-1a
shRNA no. 1 was chosen for the following experiments. The
mice were injected with Ad-PCAF shRNA no. 2 or Ad-PCAF
shRNA no. 2 in combination with Ad-PGC-1a shRNA no. 1 via
tail vein. The increases in blood glucose, Pck1 expression, and
Figure 5. PCAF Improves Glucose Homeostasis and Insulin Sensitivity in Obese Mice
(A and B) Ppargc1a, Pck1, G6pc, and Pcaf gene expressions in the lean (A) or DIO mouse (B) livers during fasting.
(C–F) Immunoblot analysis of PGC-1a, PCAF, PEPCK, andG6Pase in the livers of lean (C) or DIOmice (E) under control, fasted, or refed conditions. Densitometric
quantification of the immunoblot data in (C) and (E) are shown in (D) and (F), respectively.
(G and H) DIO mice were injected with Ad-PCAF via tail vein. Seven days later, after a 6 hr fast, blood glucose (G) and plasma insulin levels (H) were measured.
(I) mRNA levels of PCAF, PGC-1a, PEPCK, and G6Pase in liver.
(J and K) Protein levels of acetylated PGC-1a, PCAF, GCN5, PEPCK, and G6Pase in liver. Densitometric quantification of the immunoblot data in (J) is shown
in (K).
(L–N) Glucose tolerance test (L), pyruvate tolerance test (M), and insulin tolerance test (N) were performed.
(O) Insulin signaling transduction was analyzed by western blot.
(P) Densitometric quantification of the immunoblot data as shown in (O).
Values are presented as mean ± SEM with n = 8 from three independent experiments; *p < 0.05; **p < 0.01; ***p < 0.001 versus the control mice or the Ad-LacZ-
infected mice. See also Figures S3 and S4.
Figure 6. PCAF Knockdown Potentiates Hepatic Gluconeogenesis
(A) Adenovirus-mediated PCAF knockdown in the mouse liver. Mice were injected with Ad-PCAF shRNA no. 2 or Ad-LacZ shRNA via tail vein. Seven days
postinfection, PCAF mRNA levels were measured.
(B) Pck1 and G6pc expression in liver.
(C) Protein levels of acetylated PGC-1a, PCAF, PEPCK, G6Pase, and GCN5 in liver.
(D) Densitometric quantification of the immunoblot data shown in (C).
(E) Increased blood glucose levels by PCAF knockdown.
(F) Stimulation of glucose production from pyruvate by PCAF knockdown.
Values are presented as mean ± SEM with n = 5 from three independent experiments; *p < 0.05; **p < 0.01 versus the Ad-LacZ-shRNA-infected mice. See also
Figure S5.
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glucose production from pyruvate induced by PCAF knockdown
were reduced to the control levels (Figures S5C–S5E). The PCAF
knockdown-mediated upregulations of PGC-1a and PEPCK
protein levels were decreased as well (Figure S5F). These data
clearly show that PGC-1a-mediated gluconeogenesis was
stimulated by PCAF knockdown.
DISCUSSION
Our current work shows that PCAF is a key acetyltransferase that
regulates PGC-1a activity under diabetic and fasting conditions.
As a transcriptional coactivator for hepatic gluconeogenesis, the
expression level of PGC-1a is finely controlled by nutritional state
indicators such as insulin and glucagon (Herzig et al., 2001,
2003; Yoon et al., 2001). However, this control mechanism is
impaired in the obesemice. For example, PGC-1a is dramatically
increased in the obese mouse liver, even in the presence of high
insulin levels. Furthermore, PGC-1a fails to respond to the
fasting and refeeding regimen in the obese mice. These data
suggest that PGC-1a-driven hepatic gluconeogenesis is dysre-
gulated in the obesemice. In addition to the fine control by insulin
and glucagon at the transcriptional level, protein acetylation
is also an effective approach for posttranslationally regulating
PGC-1a activity. It has been reported that GCN5, another his-
tone acetyltransferase, acetylates PGC-1a to repress its activity
(Lerin et al., 2006). However, it is still unclear whether this repres-
sion effect of GCN5 on PGC-1a is correlated with the hepatic
gluconeogenesis in diabetic and fasting states. In the present
work, we observed that PCAF reversely correlates PGC-1a
both in diabetic and fasting conditions. These observations led
us to conclude that PCAF is a key negative regulator for hepatic
gluconeogenesis by affecting PGC-1a transcriptional activity.
It is worthy to note that the protein levels of both CBP and
PCAF are decreased in the obese mouse liver whereas the
protein level of p300 remains unchanged. It has been shown
that both insulin and metformin trigger the Ser436 phosphory-
lation in the CH1 domain of CBP, which causes the disassembly
of the CREB-CBP-TORC2 transcription complex and reduces
gluconeogenic enzyme expression (He et al., 2009; Zanger
et al., 2001; Zhou et al., 2004). Such insulin- or metformin-medi-
ated response is generally thought unique of CBP, as p300 lacks
an equivalent serine residue in CH1. However, some published
results suggest that CBP and p300 are both involved in the inhib-
itory effects of insulin upon hepatic gluconeogenic gene expres-
sion (Bedford et al., 2011; Liu et al., 2008). Thus, in obese mice,
the decreased CBP protein level may lead to a decline in hepatic
gluconeogenesis, which is inconsistent with the enhanced Pck1
and G6pc expression observed in obese animals (Yoon et al.,
2001). Whereas it is plausible that p300 may play a compensa-
tory role to enhance the expression of Pck1 andG6pc, its protein
level is only comparable to the lean mice. Therefore, p300 may
not be a causative factor for the unconstrained hepatic glu-
coneogenesis in obese mice. Considering our findings in the
present work, an alternative explanation for the ectopic expres-
sions in Pck1 and G6pc in obese mice is that the decreased
PCAF protein level results in enhanced PGC-1a activity, which
eventually stimulates the expression of its downstream targets,
such as Pck1 and G6pc.
Whereas PCAF stimulates proteasomal degradation of PGC-
1a, PCAF knockdown significantly enhances the protein level
of PGC-1a. Our experiments revealed that both lysine residues
(K328 and K450) in PGC-1a are acetylated by PCAF. Double
mutation (K328R/K450R) in PGC-1a almost completely abol-
ishes its degradation induced by PCAF. The protein stability
of PGC-1a is vital for the control of PGC-1a activity because of
its relatively short half-life (2 or 3 hr; Sano et al., 2007). It is well
established that PTMs play an important role in regulating
PGC-1a stability. For example, p38mitogen-activated protein ki-
nase phosphorylates PGC-1a at T262, S265, and T298 in
response to cytokine stimulation to enhance its stability in
muscle cells (Puigserver et al., 2001). Upon O-GlcNAcylation
by O-GlcNAc transferase/host cell factor C1 complex, PGC-1a
shows enhanced protein stability and hepatic gluconeogenic
transcriptional activity (Ruan et al., 2012). In our current work,
PCAF acetylates PGC-1a at K328 and K450, which subse-
quently accelerates its proteasomal degradation. Both acetyla-
tion sites were conserved among different species, and K450
was previously identified as a substrate of SIRT1 (Rodgers
et al., 2005). Our results are also consistent with the previous
observation that p300/CBP-mediated acetylation stimulates
transcriptional factor E2F1 ubiquitination after DNA damage
to cause its degradation (Galbiati et al., 2005). Acetylation of
HIF-1 at K532 by ARD1 acetyltransferase most likely enhances
its interaction with pVHL and its subsequent ubiquitination
and degradation (Jeong et al., 2002). Recently, acetylation of
cyclin-dependent kinase inhibitor p27 by PCAF was shown to
trigger the proteasomal degradation of p27 (Pe´rez-Luna et al.,
2012). However, acetylation may improve the stability for some
proteins. For example, Skp2 protein stability was enhanced
after acetylation at K68 and K71 by p300 (Inuzuka et al., 2012).
p300/CBP-mediated acetylation in p53 enhances its stability
by preventingMDM2-dependent ubiquitination, whereas deace-
tylation by HDAC1 accelerates the degradation of p53 (Ito et al.,
2002; Jin et al., 2002). Lysine ubiquitination is an important hall-
mark for ubiquitin-mediated protein degradation (Pickart, 2001).
It is highly likely that acetylation and ubiquitination compete for
the same lysine substrate in some proteins, and as a result,
lysine acetylation can enhance the stability of a protein by pre-
venting ubiquitination at the same residue from taking place.
However, it is unclear how acetylation can cause reduction in
the stability of some proteins.
SIRT1-mediated deacetylation improves PGC-1a activity
(Rodgers et al., 2005), whereas acetylation of PGC-1a by
GCN5 exhibits the opposite effect (Lerin et al., 2006). The mech-
anism underlying acetylation-mediated repression of PGC-1a
activity is still not well understood. Others have shown that
acetylation of PGC-1a by GCN5 causes a repression of PGC-
1a activity by impairing its binding capacity to the promoter
sequence of its target genes (Lerin et al., 2006). In the present
study, we observed that PCAF, an acetyltransferase, also
acetylates PGC-1a and results in a reduction in its transcriptional
activity. However, PCAF has no effects on the recruitment of
PGC-1a to Pck1 and G6pc promoters. It is also reasonable
to predict that GCN5 or PCAF itself may directly bind to gluco-
neogenic gene promoter sites and thus impairs downstream
gene expression. The results showed that GCN5 recruitment
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was decreased in the FSK/IMX-treated cells, whereas PCAF
recruitment was not affected. These results indicate that PCAF
inhibits PGC-1a activity via a different mechanism whereby
acetylation of PGC-1a by PCAF triggers its degradation. It is
possible that GCN5 and PCAF on PGC-1a may use different
lysine residues for acetylation. In the present work, we identified
two lysine residues in PGC-1a, K328 and K450, are both targets
for acetylation by PCAF, and double mutation K328R/K450R
completely abolishes the effect of PCAF. It remains to be
determined which lysine residues are targeted by GCN5 for the
acetylation of PGC-1a (Lerin et al., 2006).
Upon acetylation by PCAF, PGC-1a is prone to proteasomal
degradation, resulting in a decrease in protein stability in the
HEK293 cells. Consistent with this notion, we observed a reverse
correlation between PCAF and PGC-1a in the lean and obese
mouse livers. We also observed similar phenomena in the lean
mice under control and fasted states. These in vitro and in vivo
data suggest that PCAF is likely a negative regulator of PGC-
1a. In this case, increased expression of PCAF in liver should
lead to a decrease in the protein level of PGC-1a and its tran-
scriptional activity and eventually cause euglycemic effect in
diabetic mice. Indeed, forced ectopic expression of PCAF in
the obese mouse liver ameliorates hyperglycemia and hyperin-
sulinemia. Moreover, glucose tolerance, insulin tolerance, and
insulin signal transduction were improved as well. When we
specifically reduced PCAF expression in the lean mouse liver,
we noticed that the entire hepatic gluconeogenesis program
was stimulated by PCAF knockdown. Collectively, we propose
that PCAF is a key element for regulating PGC-1a activity that
is required for maintaining normal physiological blood glucose
level.
Our results provide strong evidence that PCAF acetyltransfer-
ase is potentially a novel target for treating disorders associated
with dysregulated hepatic glucose output, such as hyperglyce-
mia, insulin resistance, obesity, and diabetes. Specific activators
of PCAFmay be potential candidates for treating these diseases.
The two lysine residues K328 and K450 in PGC-1a are important
for the maintenance of its stability, and we demonstrated in this
study that PCAF is a key acetyltransferase for the acetylation
of PGC-1a via these two lysine residues. Future experiments
need to be conducted to identify the endogenous deacetylase
for these two sites. The reverse correlation between PCAF
and PGC-1a we observed here also exists in diseases other
than obesity and type 2 diabetes. For example, knockdown of
PCAF in colon cancer cells markedly inhibits cell migration and
represses xenograft tumorigenesis and tumor growth in nude
mice (Ge et al., 2009). Whereas PCAF inhibitors are potential
antitumor drugs, our study cautions that application of PCAF
inhibitors may stimulate PGC-1a activity and cause hypergly-
cemia. Therapeutic strategies using PCAF inhibitors for the
treatment of tumors should take into account the potential side
effects on PCG-1a and its consequence.
EXPERIMENTAL PROCEDURES
Cell Culture
293A cells were from Invitrogen. HEK293, MEF, and Hepa 1-6 cells were from
American Type Tissue Collection. H4IIE cells were kindly provided by Prof.
Wei-Fen Xie (Department of Gastroenterology of Changzheng Hospital, the
Second Military Medical University). These cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine
serum, 10 U/ml penicillin, and 1 mg/ml streptomycin at 37C and 5% CO2.
Cultures of primary hepatocytes were prepared from C57BL/6J as described
previously (Li et al., 2010). See Supplemental Experimental Procedures for a
more-detailed description.
PCAF and PGC-1a Knockdown with Adenoviral shRNAs
Adenovirus-mediated PCAF knockdown was prepared by using BLOCK-iTTM
Adenoviral RNAi Expression System (Invitrogen). Briefly, four pairs of shRNAs
against PCAF and three pairs of small hairpin RNAs against PGC-1a were
designed and synthesized at Genscript. PCAF shRNAs were then ligated
into U6 Entry vector according to the manual instruction (BLOCK-iT U6
RNAi Entry Vector Kit; Invitrogen). By using LR Clonase, PCAF shRNA
was transferred from U6 Entry vector to pAd/BLOCK-iTTM-DEST vector
(Invitrogen) for producing adenovirus bearing PCAF shRNA. The shRNA
sequences were listed in Table S2.
Adenovirus Production
Adenovirus expressing PCAF, PCAF shRNAs, PGC-1a shRNAs, PGC-1a,
PGC-1a K328R, PGC-1a K450R, or PGC-1a K328R/K450R was produced
with ViraPower Adenoviral Expression System (Invitrogen) according to
manufacturer’s instruction.
Mass Spectrometric Analysis by LC-MS/MS
To identify PGC-1a acetylation status in vivo, the HEK293 were transfected
with PGC-1a and PCAF using Lipofectamine. Thirty-six hours posttrans-
fection, HEK293 cells were treated with 1 mM trichostatin A (TSA) and 5 mM
nicotinamide (NAM) for 12 hr to inhibit the HDACs activity. HEK293 cells
were lysed with radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-
HCl [pH 7.5], 2 mM EGTA, 0.3% 3-[(3-cholamidopropyl)dimethylammonio]-
1-propanesulfonate hydrate, 100 mM NaF, 10 mM Na4P2O7, 1 mM Na3VO4,
10 mg/ml leupeptin, 10 mg/ml aproptonin, 2mMphenylmethanesulfonylfluoride
[PMSF], and 20 nM okadaic acid) containing 2 mM TSA and 10 mM NAM.
The whole-cell lysates were incubated with anti-PGC-1a antibody overnight
at 4C in the presence of 2 mM TSA and 10 mM NAM. Protein G Sepharose
beads were added for additional 2 hr. Immunoprecipitates were washed three
times with RIPA buffer containing 150 mM NaCl, 2 mM TSA, and 10 mM NAM
and boiled for 5 min in 23 Laemmli buffer for elution of immunoprecipitated
PGC-1a. Samples were resolved in SDS-PAGE and stained with Coomassie
blue. In gel digestion and reversed-phase microcapillary/tandem mass spec-
trometry (LC-MS/MS) were performed. MS/MS spectra were assigned by
searching them against the PGC-1a protein sequence using the SEQUEST
algorithm.
Total Protein Extraction from Cells and Tissues
Cells were lysed in lysis buffer (25 mM Tris-HCl [pH 7.4], 10 mM NaF, 10 mM
Na4P2O7, 2 mM Na3VO4, 1 mM EGTA, 1 mM EDTA, 1%Nonidet P-40 [NP-40],
10 mg/ml Leupeptin, 10 mg/ml Aproptonin, 1 mM PMSF, and 20 nM
Okadaic acid). After 20 min rotation at 4C, cell lysates were centrifuged at
13,200 rpm for 20 min at 4C. Tissues were homogenized with a dounce ho-
mogenizer in ice-cold tissue lysis buffer (25 mM Tris-HCl [pH 7.4], 100 mM
NaF, 50 mM Na4P2O7, 10 mM Na3VO4, 10 mM EGTA, 10 mM EDTA, 1%
NP-40, 10 mg/ml Leupeptin, 10 mg/ml Aproptonin, 2 mM PMSF, and 20 nM
Okadaic acid). After homogenization, lysates were rotated for 1 hr at 4C
and then subjected to centrifugation at 13,200 rpm for 20 min at 4C. Super-
natants were collected, and protein concentration was quantified by using
Protein Assay Kit (Bio-Rad). The concentrations of protein were normalized
with lysis buffer to have equivalent amounts of protein and volume. Protein
was denatured by boiling at 100C for 5 min in Laemmli buffer. The lysates
were cooled to room temperature before loading for western blot analysis.
Protein Stability Analysis
HEK293 cells were transfected with PGC-1a together with mock or PCAF us-
ing Lipofectamine 2000. For determining mutated PGC-1a stability, HEK293
cells were transfected with wild-type PGC-1a or PGC-1aK328R/K450R together
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with PCAF. After 36 hr posttransfection, the cells were treated with cyclohex-
imide (10 mg/ml) to inhibit protein translation initiation. At various time points,
the cells were snap frozen in liquid nitrogen. Protein levels were determined
via western blot. The intensity of PGC-1a bands were quantified, normalized
for tubulin, and plotted. Results are expressed as percentage relative to levels
observed at time 0.
Transcriptional Activity Assay
The primary mouse hepatocytes were infected with adenovirus expressing
wild-type or mutated PGC-1a together with or without adenovirus bearing
PCAF. Six hours postinfection, the culture medium was changed with fresh
medium and the cells were transfected with luciferase reporters and b-galac-
tosidase using Lipofectamine. The cells were cultured for additional 24 hr, and
luciferase and b-galactosidase enzyme activities were measured by the kits.
Relative luciferase activity was determined by normalizing to b-galactosidase
activity.
Hepatic Glucose Output
The primary mouse hepatocytes were grown in 6-well plates and infected with
indicated adenovirus. Thirty-six hours postinfection, culture medium was
replaced with 1 ml of glucose-free DMEM supplemented with 0.5% BSA,
20 mM sodium lactate, and 2 mM sodium pyruvate. After 6 hr incubation,
medium was collected and the glucose concentration was measured using
glucose oxidation kit. The readings were then normalized to the total protein
content.
Overexpression or Knockdown of PCAF in Mouse Liver
To increase expression of PCAF in the liver, 5.0 3 106 plaque-forming units
(pfu) Ad-PCAF or Ad-LacZ were injected into mice via tail vein. Four days post-
injection, blood glucose and plasma insulin were assayed in the fed animals.
Six days and eight days post-adenovirus injection, glucose tolerance test
and pyruvate tolerance test were performed, respectively. Ten days post-
adenovirus injection, insulin tolerance test was carried out. Twelve days
post-adenovirus injection, the mice were sacrificed after 6 hr of fasting for
experimental analysis. To knockdown PCAF expression in the liver, Ad-PCAF
shRNA no. 2 was injected via tail vein at the dosage of 1.53 108 pfu. Ad-LacZ
shRNA was used as a control virus. Twelve days post-adenovirus injection,
blood glucose level was measured in the fed animals. Fourteen days post-
adenovirus injection, pyruvate tolerance test was performed. Sixteen days
post-adenovirus injection, the mice were sacrificed after 6 hr of fasting for
experimental analysis.
Animal Experiments
Four-week-old male C57BL/6 mice were fed with standard diet or high-fat
diet (45% fat content) for 8 weeks. After 6 hr starvation, mice were sacrificed
and the livers were removed and snap frozen in liquid nitrogen. As for analyzing
hepatic PCAF and gluconeogenic gene expression under different nutritional
states, 7-week-old C57BL/6 mice were fed ad libitum, fasted for 24 hr, and
refed for 24 hr (Rodgers et al., 2005). The study protocol was approved by
the Institutional Animal Care and Use Committee, Model Animal Research
Center of Nantong University.
Blood Glucose and Insulin Measurements
Mice were fasted for 6 hr, after which their blood was analyzed for glucose
measurement with a glucose meter (Bayer). For insulin analysis, mice were
fasted for 12 hr and serum insulin level was measured with an Ultra-Sensitive
Mouse Insulin ELISA kit.
GTT, PTT, and ITT Assays
Glucose tolerance test (GTT) and pyruvate tolerance test (PTT) were
performed after an overnight fast (Sun et al., 2007; Zhou et al., 2011). Mice
were intraperitoneally injected with D-glucose (1 g/kg body weight) for GTT
or sodium pyruvate (2 g/kg body weight) for PTT. For insulin tolerance test
(ITT) analysis, mice were fasted for 6 hr (from 8 a.m. to 2 p.m.) and intraper-
itoneally injected with recombinant human insulin (2 IU/kg). Tail vein blood
was collected at 0, 15, 30, 60, and 120 min following glucose or sodium py-
ruvate or insulin injection, and blood glucose was measured with a glucose
meter.
Analysis of In Vivo Insulin Signaling
For in vivo insulin signaling analysis, mice were anaesthetized with xylazine/
ketamine after 6 hr of fasting. Insulin (0.75 IU/kg) or saline was infused into liver
via portal vein. Fiveminutes after infusion, livers were excised quickly, frozen in
liquid nitrogen immediately, and stored at 80C freezer until use.
Immunoprecipitation and Western Blot Analysis
Western blot analysis and immunoprecipitation procedure were performed as
previously described (Lee et al., 2011). Briefly, 1 mg lysates were incubated
with the appropriate antibody (1 or 2 mg) for 6–8 hr at 4C followed by 2 hr
incubation with Protein G Sepharose beads (Roche). Immunocomplexes
were washed five times with the cell lysis buffer before being resolved by
SDS-PAGE and immunoblotted with indicated antibodies.
Real-Time PCR
Total RNA was extracted from animal tissues using Trizol reagent and tran-
scribed into cDNA using cDNA synthesis kit. The gene expression analysis
was performed with StepOne Real-Time PCR Detection System (Applied
Biosystems) with SYBR Green Supermix. The mRNA level was normalized to
18S as a housekeeping gene. Sequences of the primers used for real-time
PCR assay were listed in Table S1.
Statistics and Data Analyses
Data are presented as a mean ± SEM. The comparisons between two
groups were performed using unpaired two-tailed Student’s t test. For
multiple-group comparisons, one-way ANOVA was applied to test for no
differences among the group means. Post hoc comparisons were adjusted
using Bonferroni corrections. Significance was accepted at *p < 0.05,
**p < 0.01, or ***p < 0.001.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
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